{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:48:09Z","timestamp":1786654089373,"version":"build-2736575974"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bcp.2026.118222","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T15:04:00Z","timestamp":1783350240000},"page":"118222","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["hIMB1636-LDM, a novel anti-TROP2 ADC, exerts potent antitumor efficacy in pancreatic cancer via direct cytotoxicity and immune activation"],"prefix":"10.1016","volume":"252","author":[{"given":"Dan-Dan","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Cheng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Rui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Yu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Jie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-Juan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Su","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cai-Yun","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Fang","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2026.118222_b0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bcp.2026.118222_b0010","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1053\/j.gastro.2023.02.012","article-title":"Pancreatic cancer: changing epidemiology and new approaches to risk assessment, early detection, and prevention","volume":"164","author":"Stoffel","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bcp.2026.118222_b0015","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1158\/2159-8290.CD-22-1066","article-title":"Efficacy of a small-molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer","volume":"13","author":"Kemp","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bcp.2026.118222_b0020","doi-asserted-by":"crossref","DOI":"10.1177\/1533033820962117","article-title":"Pancreatic cancer: a review of risk factors, diagnosis, and treatment","volume":"19","author":"Zhao","year":"2020","journal-title":"Technol. Cancer Res. Treat."},{"key":"10.1016\/j.bcp.2026.118222_b0025","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13045-024-01561-6","article-title":"Current and future immunotherapeutic approaches in pancreatic cancer treatment","volume":"17","author":"Farhangnia","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bcp.2026.118222_b0030","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.2174\/1567201818666210609161301","article-title":"targeted drug delivery: trends and perspectives","volume":"18","author":"Ashique","year":"2021","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.bcp.2026.118222_b0035","article-title":"Antibody-drug conjugates for cancer therapy, molecules (Basel","volume":"25","author":"Hafeez","year":"2020","journal-title":"Switzerland)"},{"key":"10.1016\/j.bcp.2026.118222_b0040","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bcp.2026.118222_b0045","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25136969","article-title":"Antibody-drug conjugates-evolution and perspectives","volume":"25","author":"Chis","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2026.118222_b0050","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","article-title":"Antibody-Drug Conjugates (ADCs): current and future biopharmaceuticals","volume":"18","author":"Wang","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bcp.2026.118222_b0055","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s12272-023-01433-6","article-title":"Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry","volume":"46","author":"Hong","year":"2023","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.bcp.2026.118222_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108296","article-title":"Advances in Trop2-targeted therapy: Novel agents and opportunities beyond breast cancer","volume":"239","author":"Liu","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2026.118222_b0065","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.7150\/thno.98178","article-title":"Trop2-targeted therapies in solid tumors: advances and future directions","volume":"14","author":"Liu","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.bcp.2026.118222_b0070","first-page":"746","article-title":"Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial, Annals of oncology : official journal of the European Society for","volume":"32","author":"Bardia","year":"2021","journal-title":"Med. Oncol."},{"key":"10.1016\/j.bcp.2026.118222_b0075","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1200\/JCO-24-01544","article-title":"Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III TROPION-Lung01 Study","volume":"43","author":"Ahn","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.118222_b0080","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1334938","article-title":"Corrigendum: Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132","volume":"13","author":"Cheng","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bcp.2026.118222_b0085","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1186\/s12951-023-02183-9","article-title":"TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer","volume":"21","author":"Xu","year":"2023","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.bcp.2026.118222_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.127105","article-title":"Elucidating the development, characterization, and antitumor potential of a novel humanized antibody against Trop2","volume":"253","author":"Zhou","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.bcp.2026.118222_b0095","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41698-024-00584-z","article-title":"A new TROP2-targeting antibody-drug conjugate shows potent antitumor efficacy in breast and lung cancers","volume":"8","author":"Zhou","year":"2024","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.bcp.2026.118222_b0100","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1113\/JP280389","article-title":"The ARRIVE guidelines 2.0: updated guidelines for reporting animal research","volume":"598","author":"Percie du Sert","year":"2020","journal-title":"J. Physiol."},{"key":"10.1016\/j.bcp.2026.118222_b0105","doi-asserted-by":"crossref","first-page":"W98","DOI":"10.1093\/nar\/gkx247","article-title":"GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses","volume":"45","author":"Tang","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bcp.2026.118222_b0110","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s10637-013-9995-y","article-title":"Preclinical studies of targeted therapies for CD20-positive B lymphoid malignancies by Ofatumumab conjugated with auristatin","volume":"32","author":"Li","year":"2014","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.bcp.2026.118222_b0115","doi-asserted-by":"crossref","first-page":"6645","DOI":"10.1038\/ncomms7645","article-title":"A plug-and-play approach to antibody-based therapeutics via a chemoselective dual click strategy","volume":"6","author":"Maruani","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.118222_b0120","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.actbio.2024.10.025","article-title":"Synergizing autophagic cell death and oxaliplatin-induced immunogenic death by a self-delivery micelle for enhanced tumor immunotherapy","volume":"190","author":"Deng","year":"2024","journal-title":"Acta Biomater."},{"key":"10.1016\/j.bcp.2026.118222_b0125","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1637188","article-title":"Clinical evidence that immunogenic cell death sensitizes to PD-1\/PD-L1 blockade","volume":"8","author":"Kepp","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.bcp.2026.118222_b0130","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009710","article-title":"Novel bispecific antibody-drug conjugate targeting PD-L1 and B7-H3 enhances antitumor efficacy and promotes immune-mediated antitumor responses","volume":"12","author":"Dong","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bcp.2026.118222_b0135","article-title":"Pancreatic cancer subtyping - the keystone of precision treatment","volume":"16","author":"Fan","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.118222_b0140","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41568-024-00674-x","article-title":"Immunogenic cell death in cancer: targeting necroptosis to induce antitumour immunity","volume":"24","author":"Meier","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bcp.2026.118222_b0145","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1002\/1878-0261.12851","article-title":"Targeting immunogenic cell death in cancer","volume":"14","author":"Ahmed","year":"2020","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.bcp.2026.118222_b0150","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1186\/s12967-025-06434-1","article-title":"LGALS3BP antibody-drug conjugate enhances tumor-infiltrating lymphocytes and synergizes with immunotherapy to restrain neuroblastoma growth","volume":"23","author":"Cela","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bcp.2026.118222_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114378","article-title":"Macrophage-targeting combination therapy enhances T-DXd-induced tumor regression","volume":"152","author":"Li","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bcp.2026.118222_b0160","first-page":"3291","article-title":"Radiochemotherapy in Pancreatic Cancer, current oncology (Toronto","volume":"31","author":"Domaga\u0142a-Haduch","year":"2024","journal-title":"Ont.)"},{"key":"10.1016\/j.bcp.2026.118222_b0165","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/kjm2.12375","article-title":"Mechanisms of immunogenic cell death and immune checkpoint blockade therapy","volume":"37","author":"Lin","year":"2021","journal-title":"Kaohsiung J. Med. Sci."},{"key":"10.1016\/j.bcp.2026.118222_b0170","doi-asserted-by":"crossref","DOI":"10.3390\/cells11182876","article-title":"Augmented antitumor effect of unripe Rubus coreanus miquel combined with oxaliplatin in a humanized PD-1\/PD-L1 knock-in colorectal cancer mouse model","volume":"11","author":"Lee","year":"2022","journal-title":"Cells"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226005617?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226005617?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:21:40Z","timestamp":1786652500000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226005617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":34,"alternative-id":["S0006295226005617"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118222","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"hIMB1636-LDM, a novel anti-TROP2 ADC, exerts potent antitumor efficacy in pancreatic cancer via direct cytotoxicity and immune activation","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118222","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118222"}}